Clinical Trials Logo

Filter by:
NCT ID: NCT05483205 Completed - Acne, Adult Clinical Trials

Normaderm Phytosolution Global Observational Study

Start date: July 1, 2019
Phase:
Study type: Observational

The objective of this 3-month observational study was to assess, in 2827 adults, the benefit of NP alone or as adjunctive or maintenance care in mild acne, or as adjunctive care in subjects with moderate acne.

NCT ID: NCT05476926 Recruiting - Clinical trials for Diabetic Macular Edema

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

VOYAGER
Start date: November 21, 2022
Phase:
Study type: Observational

The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products (Faricimab and Port Delivery System with Ranibizumab) in approved retinal indications (neovascular age-related macular degeneration [nAMD] and diabetic macular edema [DME]) in routine clinical practice. This study will not provide or make recommendations on use of any products including Roche products; treatment decisions will be determined by the treating physician and must be made independently to the decision to participate in this study. Participation in this study will not change or influence a patient's standard of care in any way.

NCT ID: NCT05476211 Completed - Wrinkle Clinical Trials

Safety and Efficacy of the BTL-785F Device for Non-invasive Reduction of Wrinkles

Start date: March 31, 2022
Phase: N/A
Study type: Interventional

This study will evaluate the clinical safety and the performance of the BTL-785F system for non-invasive treatment of facial wrinkles. The study is a multicenter single-arm, open-label, interventional study. The subjects will be enrolled and assigned into one experimental study arm. The subjects will be required to complete four (4) treatment visits and two follow-up visits.

NCT ID: NCT05469503 Active, not recruiting - Metabolic Syndrome Clinical Trials

Effect of TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure

INSIGHT
Start date: July 15, 2022
Phase: N/A
Study type: Interventional

This clinical study aims to assess the efficacy of TOTUM-854, a mix of 6 plant extracts, consumed twice a day on automated office blood pressure in subjects with moderately elevated blood pressure. The hypothesis is that TOTUM-854 is superior to placebo for decrease of automated office blood pressure after 12 weeks of consumption.

NCT ID: NCT05467163 Recruiting - Heart Failure Clinical Trials

Conduction System Pacing Versus Biventricular Pacing After Atrioventricular Node Ablation

CONDUCT-AF
Start date: July 18, 2023
Phase: N/A
Study type: Interventional

Atrioventricular node ablation (AVNA) with biventricular (BiV) pacemaker implantation is a feasible treatment option in patients with symptomatic refractory atrial fibrillation and heart failure. However, conduction system pacing (CSP) modalities, including His bundle pacing and left bundle branch pacing, could offer advantages over BiV pacing by providing more physiological activation. The randomized, interventional, multicentric study will explore whether CSP is non-inferior to BiV pacing in echocardiographic and clinical outcomes in heart failure (EF <50%) patients with symptomatic AF and narrow QRS scheduled for AVNA.

NCT ID: NCT05461170 Recruiting - Clinical trials for Hepatitis D, Chronic

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

Start date: September 17, 2022
Phase: Phase 2
Study type: Interventional

This is a phase 2 trial in which participants with chronic hepatitis D virus (HDV) infection will receive VIR-2218 and/or VIR-3434 and be assessed for safety, tolerability, and efficacy

NCT ID: NCT05460832 Completed - Clinical trials for Rheumatoid Arthritis

Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA

Start date: August 29, 2022
Phase: Phase 2
Study type: Interventional

Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments. MBS2320, the drug being tested in this trial, represents a new approach to treating RA, with the potential not only to reduce levels of inflammation but to also directly prevent bone damage. The aim of this project is to test the safety, tolerability and efficacy of MBS2320 in patients with RA in combination with an existing treatment, methotrexate. Approximately 224 participants with moderate to severe active RA who have not responded to treatment with Methotrexate will be enrolled from around 45 to 55 sites around the world. Participants will be randomly assigned to receive 1 of 3 doses of MBS2320 (5 mg, 20 mg, or 40 mg) or placebo (a "dummy" drug). The maximum duration of study participation for a participant will be 22 weeks, which consists of a Screening Period of up to 4 weeks, Treatment Period of 12 weeks, and a Follow-up Period of 6 weeks. Participants on the study will be asked to attend the hospital or clinic for regular visits during which they will have planned study assessments to evaluate the effectiveness, tolerability and safety of the study drug.

NCT ID: NCT05460065 Recruiting - Pharmacokinetics Clinical Trials

Single and Multiple Intravenous Administrations of Estetrol (E4) in Healthy Adult Volunteers

Start date: April 4, 2022
Phase: Phase 1
Study type: Interventional

The Sponsor intends to develop an intravenous (i.v.) formulation of E4 for the treatment of neonatal hypoxic-ischemic encephalopathy (NHIE). E4 has not been administered intravenously to humans yet. This single-center, double-blind, placebo-controlled randomized study aims to evaluate the safety, tolerability, and PK of an i.v. E4 solution administered as single-dose or multiple dose to healthy adult volunteers.

NCT ID: NCT05456191 Recruiting - Clinical trials for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

ASC4START
Start date: November 21, 2022
Phase: Phase 3
Study type: Interventional

The study is designed to compare the tolerability of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP).

NCT ID: NCT05455684 Recruiting - Clinical trials for Depressive Disorder, Major

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

VENTURA-1
Start date: June 22, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with moderate-to-severe anhedonia (ANH+) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).